WOSULIN-30/70 DISPOPEN

Distributor inventory

Treatment of diabetes mellitus to improve blood glucose control in patients requiring insulin (Type 1 diabetes and insulin-requiring Type 2 diabetes).

Biphasic human insulin provides both rapid and intermediate action. The soluble (regular) component covers post-meal glucose rise, while the NPH (isophane) component provides basal control between meals and overnight by facilitating glucose uptake and reducing hepatic glucose output.

For subcutaneous injection using the prefilled disposable pen as prescribed by a doctor. Usually given 1–2 times daily about 30 minutes before meals; rotate injection sites (abdomen, thigh, upper arm) to reduce lipodystrophy. Do not inject intravenously; check appearance and resuspend as applicable for biphasic insulin before use; follow pen instructions for priming and dosing.

Hypoglycaemia, injection site pain/redness/swelling, lipodystrophy, weight gain, rash/itching, oedema

Hypoglycaemia is the most common and serious risk—carry glucose/sugar and educate on symptoms. Dose needs adjustment with changes in diet, exercise, illness, renal/hepatic impairment, or when switching insulin types/brands. Use caution in elderly and those with kidney or liver disease. Do not share pens/needles. Avoid use if allergic to insulin or excipients. Driving/operating machinery may be impaired by hypo/hyperglycaemia.